Alapsis SA, based in Greece, have announced that they have acquired a 100% stake in Labomed SA, at a price of € 2 millon.
Labomed is headquartered in Athens and it is active since 1996 in the trade of medical and laboratory equipment both in the private and the public sector.
More specifically the company trades diagnostic equipment (haematologic, biochemical and microbiological), having acquired a significant market share in the coagulation and
thrombosis disease, diagnosis and control.
Labomed represents foreign firms, mainly from Europe, and is the exclusive Greek representative in Greece of Axis-Shield Norway, which specialises in diabetes control and diagnosis.
The company’s current management will remain in place, according to Alapis.
During the 2006 financial year, the Labomed’s turnover, earnings before interest tax and depreciation (EBITDA) and its earnings before tax (EBT) amounted to €2 million, € 567,000
and € 400,000 respectively.
For the 2007 financial year, the company’s turnover, EBITDA, EBT are expected to reach € 2.5 million, € 950,000 and € 870,000 respectively.
Last month Alapis announced the purchase of Lamda Applied, a pharmaceutical laboratory. The acquisition value of the shares amounted to €475,000.